Thomas P. Schnettler - Jun 1, 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Director
Signature
/s/ Thomas P. Schnettler, by Brian McKelligon, as Attorney-in-Fact
Stock symbol
AKYA
Transactions as of
Jun 1, 2022
Transactions value $
$0
Form type
4
Date filed
6/3/2022, 04:08 PM
Previous filing
May 20, 2022
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKYA Common Stock 2.81M Jun 1, 2022 Held by Piper Sandler Merchant Banking Fund II, L.P. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Stock Option (Right to Buy Award $0 +30.5K $0.00 30.5K Jun 1, 2022 Common Stock 30.5K $11.24 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 PSC Capital Management II LLC is the general partner of Piper Sandler Merchant Banking Fund II, L.P. Piper Sandler Companies is the manager of PSC Capital Management II LLC. The reporting person is the Co-CEO of PSC Capital Management II LLC and disclaims beneficial ownership of the shares held by Piper Sandler Merchant Banking Fund II, L.P.
F2 Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2023 or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.